Study on MK-6070 for Advanced Cancers with DLL3 Expression

Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04471727

Provider View

This clinical trial is exploring the safety and effectiveness of a new drug, MK-6070, alone and in combination with other treatments, for patients with advanced cancers that express a protein called DLL3.

Patient Parameters

Program Overview

The purpose of this study is to find the best dose and evaluate the safety and effectiveness of MK-6070, a new drug being tested for advanced cancers that have a protein called DLL3. The study will also look at how MK-6070 works when used with other treatments like Atezolizumab and I-DXd.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of cancer that expresses the DLL3 protein.
  • Have small cell lung cancer (SCLC) that has returned or not responded to at least one previous treatment, including platinum-based chemotherapy.
  • Have Neuroendocrine Prostate Cancer (NEPC) that has returned or not responded to standard treatments.
  • Have other high-grade neuroendocrine tumors that:
    • Have returned or not responded to standard treatments.
    • Do not have a standard treatment available.
    • Are not suitable for standard treatment as decided by the doctor.
  • Must be able to provide a previous or new tissue sample for testing.

Exclusion Criteria

  • Have untreated cancer that has spread to the brain or spinal cord.
  • Have a type of brain cancer or other primary brain tumors.
  • Have spinal cord compression or uncontrolled disease around the spine.
  • Have a history of bleeding in the brain or spinal cord.
  • Have active neurological conditions related to cancer.
  • Have uncontrolled fluid buildup around the lungs, heart, or abdomen that needs frequent drainage.
  • Have a history of autoimmune diseases or immune deficiencies, such as lupus or rheumatoid arthritis.
  • Are currently taking medications that suppress the immune system, like high-dose steroids, within two weeks before starting the study.
  • Have had significant heart disease or stroke within the last six months.
  • Have active hepatitis A, B, or C infections, unless well-controlled.
  • Have uncontrolled HIV infection, unless well-controlled.
  • Have had a stem cell or organ transplant.
  • Have taken immune-boosting drugs like interferon within four weeks before starting the study.
  • Have had severe allergic reactions to certain types of antibodies.
  • Have a history of lung diseases like pulmonary fibrosis or pneumonitis, unless related to past radiation treatment.
  • Have taken another investigational drug within three weeks before starting the study.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.